News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
241 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39672)
2015 (44431)
2016 (38329)
2017 (37187)
2018 (39119)
2019 (51334)
2020 (57662)
2021 (58720)
2022 (53927)
2023 (42564)
2024 (37440)
2025 (33091)
2026 (28303)
Month
January (4681)
February (5217)
March (5801)
April (5232)
May (5822)
June (5224)
July (4072)
August (4645)
September (4518)
October (4153)
November (5533)
December (3822)
Day
1 (240)
2 (57)
3 (1)
4 (1)
5 (18)
6 (241)
7 (241)
8 (238)
9 (112)
10 (3)
11 (4)
12 (212)
13 (193)
14 (224)
15 (199)
16 (95)
17 (5)
18 (3)
19 (174)
20 (211)
21 (192)
22 (230)
23 (101)
24 (8)
25 (6)
26 (208)
27 (213)
28 (252)
29 (279)
30 (110)
31 (1)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Biotech Beach
Metacrine to Present New Preclinical Data in Inflammatory Bowel Disease (IBD) at European Crohn’s and Colitis Organisation (ECCO) 2021 Virtual Congress
Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that it will present new preclinical data at the European Crohn’s and Colitis Organisation (ECCO) 2021 Virtual Congress on July 9, 2021.
July 6, 2021
·
3 min read
Rosinbomb™ Announces Exclusive Product Collaboration With ArdentIndustry Leaders Team Up to Create First Ever Extraction Press/ Infuser Combination in Time for 710!
ROSINBOMB (OTC:ROSN) and ARDENT industry leading developers and manufacturers of highly acclaimed groundbreaking solventless extraction and infusion technology products announced today the launch of two exclusive limited edition solution bundles in time for 710.
July 6, 2021
·
4 min read
Drug Development
Longeveron Announces First Patient Treated in Phase 2b Hypoplastic Left Heart Syndrome (HLHS) Clinical Study
Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today that the first patient has been enrolled and treated in the Phase 2b clinical study evaluating Lomecel-B intraventricular injection in infants with Hypoplastic Left Heart Syndrome (HLHS).
July 6, 2021
·
6 min read
Drug Development
Ascendis Pharma A/S Announces Target Enrollment Achieved in the Phase 3 PaTHway Trial of TransCon™ PTH (palopegteriparatide) in Adults with Hypoparathyroidism (HP) and Provides a Comprehensive Global Clinical Program Update
Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create new product candidates that address unmet medical needs, today announced it has reached the target enrollment in the phase 3 PaTHway Trial, a trial evaluating the safety, tolerability, and efficacy of TransCon PTH (palopegteriparatide) in addition to providing a comprehensive global clinical program update.
July 6, 2021
·
9 min read
Lone Star Bio
Molecular Templates to Present at the Ladenburg Thalmann 2021 Healthcare Conference
Molecular Templates, Inc. announced that it will provide a corporate update and participate in 1-on-1 investor meetings at the Ladenburg Thalmann 2021 Healthcare Conference, to take place July 13-14, 2021.
July 6, 2021
·
1 min read
Policy
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi SyndromeFDA agrees to review additional data to determine adequacy for submission of NDA
Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update following a recent interaction with the U.S. Food and Drug Administration (FDA) regarding the development of once-daily DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi Syndrome (PWS).
July 6, 2021
·
5 min read
BioCapital
Nobelpharma America Announces Presence at 2021 Society for Pediatric Dermatology Annual Meeting
Nobelpharma America, LLC, a pharmaceutical and medical device company headquartered in Bethesda, Maryland, today announced its involvement at the 2021 Society for Pediatric Dermatology (SPD) Annual Meeting July 8-10, 2021.
July 6, 2021
·
3 min read
Lipocine To Present At The Ladenburg Thalmann Healthcare Conference
Lipocine Inc. today announced that the Company will present at the Ladenburg Thalmann Healthcare Conference. The conference will be held virtually.
July 6, 2021
·
2 min read
Business
Viracta Therapeutics Announces the Appointment of Ayman El-Guindy, Ph.D., as Chief Scientific Officer and Key Additions to Management Team
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Ayman El-Guindy, Ph.D., as Chief Scientific Officer.
July 6, 2021
·
9 min read
Drug Development
Eiger BioPharmaceuticals Announces First Patients Dosed with Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Outpatients
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the first patients were dosed with Peginterferon Lambda (Lambda) in the Phase 3 TOGETHER platform study in outpatients with COVID-19.
July 6, 2021
·
5 min read
Previous
12 of 25
Next